The relationship between BMI, plasma leptin, insulin and proinsulin before and after laparoscopic adjustable gastric banding

Obesity Surgery

Volumn 15, Issue 10, 2005, Pages 1456-1462

  Ram, Edward ^a,b   Vishne, Tali ^a,b   Maayan, Rachel ^b   Lerner, Igor ^a,b   Weizman, Abraham ^b   Dreznik, Zeev ^a,b   Konstantin, Bloch ^b   Seror, D ^a,b   Pnina, Vardi ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Insulin; Laparoscopic gastric banding; Leptin; Morbid obesity; Proinsulin; Weight loss

Indexed keywords

INSULIN; LEPTIN; PROINSULIN;

AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BODY MASS; FOLLOW UP; GASTRIC BANDING; HUMAN; INSULIN BLOOD LEVEL; LAPAROSCOPIC SURGERY; MORBID OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURGICAL PATIENT; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; GASTROPLASTY; HUMANS; INSULIN; LAPAROSCOPY; LEPTIN; MALE; MIDDLE AGED; OBESITY, MORBID; PROINSULIN; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 28544437393     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/096089205774859146     Document Type: Article

References (63)

1. Green SM. Obesity: prevalence, causes, health risks and treatment. Br J Nurs 1997; 6: 1181-5.
2. Hubert HB, Feinleib M, McNamara PM et al. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
3. Kanders BS, Blackburn GL, Lavin PT et al. Weight loss outcome and health benefits associated with the Optifast program in the treatment of obesity. Int J Obes 1989; 13: 131-4.
4. Pories WJ. Why does the gastric bypass control type 2 diabetes mellitus? Obes Surg 1992; 2: 303-13.
5. Ponce J, Haynes B, Paynter S et al. Effect of Lap-Band®-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg 2004; 14: 1335-42.
6. Gumbs AA, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of calorie restriction and weight loss. Obes Surg 2005; 15: 462-73.
7. Gleysteen JJ. Results of surgery: long-term effects on hyperlipidemia. Am J Clin Nutr, 1992; 55 (Suppl 2): 591S-593S.
8. Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-6.
9. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
10. Ahima RS, Prabakaran D, Mantzoros CS et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-2.
11. Ahima RS, Dushay J, Flier SN et al. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 1997; 99: 391-5.
12. Herman ML, Ahima RS, Craft LS et al. Leptin inhibition of the hypothlamic-pituitary-adrenal axis in response to stress. Endocrinology 1997; 138: 3859-63.
13. Yu WH, Kimura M, Walczewska A et al. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S 1997; A94: 1023-8.
14. Ahrén B, Larsson H. Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women. Diabetes 2002; 52: S202-S211.
15. Bergman, RN, Ader M, Huecking K et al. Accurate assessment of -cell function. Diabetes 2002; 52: S212-S220.
16. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68: 1456-67.
17. Kahn SE. The importance of -cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-58.
18. Kahn, SE, Prigeon RL, McCulloch SK et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-72.
19. Brolin RE. Gastrointestinal surgery for severe obesity. NIH Consensus Conference. Nutrition 1996; 12: 403-4.
20. Grace DM. Gastric reduction procedures for treating severe obesity. Am J Clin Nutr 1992; 55: S556-S559.
21. Pories WJ, MacDonald KG Jr, Morgan EJ et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow up. Am J Clin Nutr 1992; 55: 582S-585S.
22. Zehetner J, Holzinger F, Triaca H et al. A 6-year experience with the Swedish adjustable gastric band. Prospective long-term audit of laparoscopic gastric banding. Surg Endosc 2005; 19: 21-8.
23. Widhalm K, Dietrich S, Prager G. Adjustable gastric banding surgery in morbidly obese adolescents: experiences with eight patients. Int J Obes 2004; 28 (Suppl 3): S42-45.
24. Kormanova K, Fried M, Hainer V et al. Is laparoscopic adjustable gastric banding a day surgery procedure? Obes Surg 2004; 14: 1237-40.
25. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37.
26. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
27. Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996; 81: 3424-7.
28. Rosenbaum M, Nicolson M, Hirsch J et al. Effect of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab 1997; 82: 3647-54.
29. Maffei, M, Halaas, JL, Ravussin E et al. Leptin levels in human and rodents: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1995; 1: 1155-61.
30. Toornvliet AC, Piji H, Frolich M et al. Insulin and leptin concentrations in obese humans during long-term weight loss. Neth J Med 1997; 51: 96-102.
31. Weigle D, Duell P, Connor W et al. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J Clin Endocrinol Metab 1997; 82: 561-5.
32. Maffei M, Halaas J, Ravussin E et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1996; 1: 1155-61.
33. Havel PJ, Kasim-Karkas S, Mueller W et al. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996; 81: 4406-13.
34. Infanger D, Baldinger R, Branson R et al. Effect of significant intermediate-term weight loss on serum leptin levels and body composition in severely obese subjects. Obes Surg 2003; 13: 879-88.
35. Naslund E, Andersson I, Degerblad M et al. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. J Intern Med 2000; 248: 299-308.
36. Nijhuis J, van Dielen FM, Buurman WA et al. Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg 2004; 14: 783-7.
37. Uzun H, Zengin K, Taskin M et al. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004; 14: 659-65.
38. Zabrocka L, Raczynska S, Goyke E et al. BMI is the main determinant of the circulating leptin in women after vertical banded gastroplasty. Obes Res 2004; 12: 505-12.
39. Geloneze B, Tambascia MA, Pareja JC et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg 2001; 11: 693-8.
40. Guldstrand M, Backman L, Adamson U et al. Lowering of circulating insulin and leptin is closely associated following weight reduction after vertical banded gastroplasty in obese women. Diabetes Obes Metab 1999; 1: 53-5.
41. de Marinis L, Mancini A, Valle D et al. Plasma leptin levels after biliopancreatic diversion: dissociation with body mass index. J Clin Endocrinol Metab 1999; 84: 2386-9.
42. Molina A, Vendrell J, Gutierrez C et al. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003; 13: 615-21.
43. Zimmet P, Hodge A, Nicolson M et al. Serum leptin concentration, obesity and insulin resistance in Western Samoans: cross-sectional study. BMJ 1996; 313: 965-9.
44. Fischer S, Hanefeld M, Haffner SM et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002; 39: 105-10.
45. Carmichael AR, Johnston D, King RF et al. Effects of the Magenstrasse and Mill operation for obesity on plasma leptin and insulin resistance. Diabetes Obes Metab 2001; 3: 99-103.
46. Carmichael AR, Tate G, King RF et al. Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin. Pathophysiol Haemost Thromb 2002; 32: 40-3.
47. Yashkov YI, Vinnitsky LI, Poroykova MV et al. Some hormonal changes before and after vertical banded gastroplasty for severe obesity. Obes Surg 2000; 10: 48-53.
48. Hanusch-Enserer U, Cauza E, Spak M et al. Improvement of insulin resistance and early atherosclerosis in patients after gastric banding. Obes Res 2004; 12: 284-91.
49. Yoshida Y, Hashimoto N, Tokuyama Y et al. Effects of weight loss in obese subjects with normal fasting plasma glucose or impaired glucose tolerance on insulin release and insulin resistance according to a minimal model analysis. Metabolism 2004; 53: 1095-100.
50. Hansen BC. Obesity, diabetes, and insulin resistance: implications from molecular biology, epidemiology, and experimental studies in humans and animals. Synopsis of the American Diabetes Association's 29th Research Symposium and Satellite Conference of the 7th International Congress on Obesity, Boston, Massachusetts. Diabetes Care 1995; 18: A2-9.
51. Muscelli E, Mingrone G, Camastra S et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 2005; 118: 51-7.
52. Kopp HP, Kopp CW, Festa A et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-7.
53. Gazzaruso C, Giordanetti S, La Manna A et al. Weight loss after Swedish Adjustable Gastric Banding: relationships to insulin resistance and metabolic syndrome. Obes Surg 2002; 12: 841-5.
54. Pereira JA, Claro BM, Pareja JC et al. Restored insulin inhibition on insulin secretion in nondiabetic severely obese patients after weight loss induced by bariatric surgery. Int J Obes 2003; 27: 463-8.
55. Haffner SM, Gonzalez C, Mykkännen L et al. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to type 2 diabetes: the Mexico City Diabetes Study. Diabetologia 1997; 40: 830-7.
56. Nijpels G, Popp-Snijders C, Kostense PJ et al. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to type 2 diabetes in subjects with impaired glucose tolerance: the Hoorn study. Diabetologia 1996; 39: 113-8.
57. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46: 1725-1732.
58. Røder ME, Porte D, Schwartz RS et al. Disproportionately elevated proinsulin levels reflect the degree of impaired β-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 604-8.
59. Festa A, D'Agostino R, Mykkänen L et al LDL particle size in relation to insulin, proinsulin, and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 1688-93.
60. Kubo K: Effect of Pioglitazone on blood proinsulin levels in patients with type 2 diabetes. Endocr J 2002; 49: 323-8.
61. Letiexhe MR, Scheen AJ, Gerard PL et al. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes 1994; 18: 295-300.
62. Jimenez J, Zuniga-Guajardo S, Zinman B et al. Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab 1987; 64: 661-8.
63. Guldstrand M, Ahren B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 2003; 284: E557-65.